🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 66 of 857 · Phase 3 first, then by program name

  1. Experimental vaccine

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 3 mab completed

    1 trial

  2. Experimental: Tezepelumab

    AstraZeneca

    Asthma

    phase 3 mab completed

    1 trial

  3. Experimental: Venetoclax in combination with Decitabine (+-sorafenib)

    Kunming Hope of Health Hospital

    Elderly AML Patients

    phase 3 other active

    1 trial

  4. Expressive Writing

    United Therapeutics Europe Ltd

    Posttraumatic Stress Disorder

    phase 3 other completed

    1 trial

  5. Extended Release Buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorder

    phase 3 small molecule completed

    1 trial

  6. Extended Release Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 3 small molecule completed

    1 trial

  7. Extended treatment

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 3 small molecule completed

    1 trial

  8. Extended-release Guanfacine HCl (Intuniv, SPD503)

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  9. Extended-release Guanfacine Hydrochloride

    Takeda

    Attention-deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    3 trials

  10. Extensively Hydrolyzed formula

    United Therapeutics Europe Ltd

    Cow Milk Allergy

    phase 3 other completed

    1 trial

  11. Eylea (Aflibercept, BAY86-5321)

    Regeneron UK Limited

    Retinopathy of Prematurity (ROP)

    phase 3 small molecule completed

    2 trials

  12. Eylea 40 mg/mL solution for injection in a vial

    Lacuna Pharma Pty Ltd

    Retinopathy of prematurity (ROP)

    phase 3 small molecule active

    1 trial

  13. FAMPRIDINE, Placebo 515

    Pari Pharma GmbH

    Spinocerebellar ataxia

    phase 3 small molecule active

    1 trial

  14. FAT EMULSIONS , Triheptanoin

    Lacuna Pharma Pty Ltd

    Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

    phase 3 small molecule active

    1 trial

  15. FE 999326

    Ferring Pharmaceuticals

    Bladder Cancer

    phase 3 small molecule active

    1 trial

  16. FE 999913 vaginal tablet

    Ferring Pharmaceuticals

    Luteal Hormone Supplementation

    phase 3 small molecule completed

    1 trial

  17. FEIBA

    Takeda

    Hemophilia A or B With Inhibitors

    phase 3 mab completed

    1 trial

  18. FET

    Disc Medicine

    ACTH-dependent hypercortisolism

    phase 3 small molecule active

    1 trial

  19. FF

    GlaxoSmithKline

    Rhinitis, Allergic, Perennial

    phase 3 small molecule completed

    1 trial

  20. FF/GW642444 Inhalation Powder

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 3 small molecule completed

    2 trials

  21. FF/UMEC/VI

    GlaxoSmithKline

    Asthma

    phase 3 small molecule active

    1 trial

  22. FF/UMEC/VI

    Grace Therapeutics

    Asthma

    phase 3 small molecule active

    1 trial

  23. FIBRINOGEN, HUMAN, RIVAROXABAN , APIXABAN , ETAMSYLATE , TRANEXAMIC ACID , -, PROTAMINE , -, ERYTHROCYTES , AMINOMETHYLBENZOIC ACID , -, AMINOCAPROIC ACID , Ondexxya 200 mg powder for solution for infusion, EDOXABAN , -

    AstraZeneca AB

    Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.

    phase 3 small molecule active

    1 trial

  24. FILGRASTIM, CYCLOPHOSPHAMIDE, DOXORUBICIN, DEXRAZOXANE HYDROCHLORIDE

    Ningbo Cancer Hospital

    Advanced or metastatic soft tissue sarcoma (STS) in patients ≥65 years old

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources